Dr Aymen I Idris

MSc, PhD

Department of Oncology and Metabolism

Senior Lecturer

aymen.idris@sheffield.ac.uk
+44 114 215 9051

+44 114 271 2475 (fax)

Room DU38, The Medical School

Full contact details

Dr Aymen I Idris
Department of Oncology and Metabolism
Room DU38
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries, please contact - om-operationalteam@sheffield.ac.uk

I am a Pharmacologist and Senior Lecturer in pharmacology at the Department of Oncology & Metabolism, University of Sheffield (England, UK). My interest in musculoskeletal pharmacology began in 2000 when I joined Professor Stuart H. Ralston's group at the University of Aberdeen (Scotland, UK), where I obtained a PhD in Medicine and underwent my early postdoctoral training.

One of my particular areas of interests during this period was the effect of cannabis-like substances on bone biology and pharmacology. In this area, I carried out significant research on the skeletal effects of endocannabinoids and their receptors on bone biology with publications in Nature Medicine, Cell Metabolism and Aging Cell.

I also conducted research into the role of the NFkB signalling pathway in bone disease resulting in a number of publications in Endocrinology, FASEB J and JBMR, and a series of patents of a novel family of NFkB inhibitors, which exhibit anti-resorptive, anti-inflammatory and anti-tumour properties. Between 2010 and 2013, I held a position of non-clinical lecturer in cancer associated bone disease at Edinburgh Cancer Research UK Centre at the University of Edinburgh (Scotland, UK).

During this period, my group developed a number of model systems to study tumour – immune - bone cell interactions in vitro, ex vivo and in vivo, a system we have successfully utilized in our research and publications in Cancer Letters, Oncotarget and J.Bio.Chem.

I graduated with a BSc (Hons) degree from University of Sunderland, UK, and I obtained an MSc in Pharmacology working in Professor G. H. Hawksworth’s laboratory at the university of Aberdeen.

Research interests

The primary interest of my group is pharmacology of inflammation. The specific aims of our research are to:

uncover novel druggable pro-inflammatory transduction pathways essential for the regulation of cancer – immune - bone cell interactions, and guided by these studies
design and test novel therapeutic agents - alone or in combination with drugs in clinical practice - for the treatment of chronic inflammation associated with bone diseases and cancer.

Current Projects

Targeting of IKK-Epsilon alone or in combination with chemotherapeutic drugs for breast cancer treatment.
Regulation of adipocyte – cancer cell crosstalk by NFkB signalling.
Role of TRAFs/NFkB signalling in inflammation associated with metastatic cancer.
Role of RANK/NFkB signalling in cancer cell behaviour in bone.
Regulation of bone – immune – malignant cell interactions by the Endocannabinoid/NFkB axis.

Publications

Show: Featured publications All publications

Featured publications

Chapters

Sophocleous A & Idris AI (2019) Ovariectomy/Orchiectomy in Rodents, Methods in Molecular Biology (pp. 261-267). Springer New York
Marino S & Idris AI (2019) Analysis of Signaling Pathways by Western Blotting and Immunoprecipitation, Methods in Molecular Biology (pp. 131-143). Springer New York

All publications

Books

Idris AI (2019) Bone Research Protocols. Humana Press.
Idris AI (2019) Preface.

Journal articles

Bishop RT, Marino S, Carrasco G, Li B, Allen RJ, Sparatore A, Ottewell PD, Mollat P, Sims AH, Capulli M , Wang N et al (2020) Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 488, 27-39.
Marino S, Carrasco G, Li B, Shah KM, Lath DL, Sophocleous A, Lawson MA & Idris AI (2020) JZL184, a monoacylglycerol lipase inhibitor, induces bone loss in a multiple myeloma model of immunocompetent mice. Calcified Tissue International. View this article in WRRO
Marino S, de Ridder D, Bishop RT, Renema N, Ponzetti M, Sophocleous A, Capulli M, Aljeffery A, Carrasco G, Gens MD , Khogeer A et al (2019) Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine, 44, 452-466. View this article in WRRO
Bishop RT, Marino S, de Ridder D, Allen RJ, Lefley DV, Sims AH, Wang N, Ottewell PD & Idris AI (2019) Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Letters, 450, 76-87. View this article in WRRO
Marino S, Bishop RT, Carrasco G, Logan JG, Li B & Idris AI (2019) Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo. Calcified Tissue International, 1-12. View this article in WRRO
Beattie JR, Sophocleous A, Caraher MC, O’Driscoll O, Cummins NM, Bell SEJ, Towler M, Rahimnejad Yazdi A, Ralston SH & Idris AI (2019) Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis. Journal of Materials Science: Materials in Medicine, 30(2).
De Ridder D, Marino S, Bishop RT, Renema N, Chenu C, Heymann D & Idris AI (2018) Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A. Scientific Reports, 8(1). View this article in WRRO
Marino S, Bishop RT, Capulli M, Sophocleous A, Logan JG, Mollat P, Mognetti B, Ventura L, Sims AH, Rucci N , Ralston SH et al (2018) Regulation of breast cancer induced bone disease by cancerspecific IKKβ. Oncotarget, 9(22), 16134-16148. View this article in WRRO
Marino S, Bishop RT, Mollat P & Idris AI (2018) Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis. Calcified Tissue International. View this article in WRRO
Clare Caraher M, Sophocleous A, Renwick Beattie J, O'Driscoll O, Cummins NM, Brennan O, O'Brien FJ, Ralston SH, Bell SEJ, Towler M & Idris AI (2018) Raman spectroscopy predicts the link between claw keratin and bone collagen structure in a rodent model of oestrogen deficiency. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1864(2), 398-406. View this article in WRRO
Peramuhendige P, Marino S, Bishop RT, de Ridder D, Khogeer A, Baldini I, Capulli M, Rucci N & Idris AI (2018) TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis. Scientific Reports, 8(1). View this article in WRRO
Marino S, Bishop RT, Logan JG, Mollat P & Idris AI (2017) Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis. Cancer Letters, 410, 180-190. View this article in WRRO
Sophocleous A, Marino S, Kabir D, Ralston SH & Idris AI (2017) Combined deficiency of the Cnr1 and Cnr2 receptors protects against age‐related bone loss by osteoclast inhibition. Aging Cell, 16(5), 1051-1061. View this article in WRRO
Marino S & Idris A (2017) Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. Pharmacological Research, 119, 391-403. View this article in WRRO
Sophocleous A, Marino S, Logan JG, Mollat P, Ralston SH & Idris AI (2015) Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis. Journal of Biological Chemistry, 290(36), 22049-22060.
Sophocleous A & Idris AI (2014) Rodent models of osteoporosis. BoneKEy Reports, 3.
Sophocleous A, Sims AH, Idris AI & Ralston SH (2014) Modulation of Strain-Specific Differences in Gene Expression by Cannabinoid Type 2 Receptor Deficiency. Calcified Tissue International, 94(4), 423-432.
Sophocleous A, Idris AI & Ralston SH (2014) Genetic Background Modifies the Effects of Type 2 Cannabinoid Receptor Deficiency on Bone Mass and Bone Turnover. Calcified Tissue International, 94(3), 259-268.
Logan JG, Sophocleous A, Marino S, Muir M, Brunton VG & Idris AI (2013) Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis. Journal of Bone and Mineral Research, 28(5), 1229-1242.
Idris AI & Ralston SH (2012) Role of cannabinoids in the regulation of bone remodeling. Frontiers in Endocrinology, 3. View this article in WRRO
Frantzias J, Logan JG, Mollat P, Sparatore A, Del Soldato P, Ralston SH & Idris AI (2012) Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. British Journal of Pharmacology, 165(6), 1914-1925.
Idris AI (2012) The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. BoneKEy Reports, 1, 224-224.
Idris AI (2012) Analysis of Signalling Pathways by Western Blotting and Immunoprecipitation, 223-232.
Idris AI (2012) Ovariectomy/Orchidectomy in Rodents, 545-551.
Sophocleous A, Landao-Bassonga E, van‘t Hof RJ, Idris AI & Ralston SH (2011) The Type 2 Cannabinoid Receptor Regulates Bone Mass and Ovariectomy-Induced Bone Loss by Affecting Osteoblast Differentiation and Bone Formation. Endocrinology, 152(6), 2141-2149.
Idris AI (2011) The promise and dilemma of cannabinoid therapy: Lessons from animal studies of bone disease. IBMS BoneKEy, 8(2), 84-95.
Idris AI, Coste E, Greig IR, Ralston SH & van’t Hof RJ (2010) The Biphenyl-Carboxylate Derivative ABD328 is a Novel Orally Active Antiresorptive Agent. Calcified Tissue International, 87(6), 525-532.
Idris AI, Krishnan M, Simic P, Landao‐Bassonga E, Mollat P, Vukicevic S & Ralston SH (2010) Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy‐induced bone loss in vivo. The FASEB Journal, 24(11), 4545-4555.
Idris AI & Ralston SH (2010) Cannabinoids and Bone: Friend or Foe?. Calcified Tissue International, 87(4), 285-297.
Sophocleous⁎ A, Landao-Bassonga E, van 't Hof R, Ralston SH & Idris AI (2010) The type 2 cannabinoid receptor protects against age-related bone loss and ovariectomy induced bone loss by stimulating bone formation. Bone, 47, S42-S43.
Idris AI, Mrak E, Greig I, Guidobono F, Ralston SH & van ‘t Hof R (2010) Corrigendum to “ABD56 causes osteoclast apoptosis by inhibiting the NFκB and ERK pathways” [Biochem. Biophys. Res. Commun. 371 (2008) 94–98]. Biochemical and Biophysical Research Communications, 395(2), 289-289.
Idris AI, Landao-Bassonga E & Ralston SH (2010) The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone, 46(4), 1089-1099.
I. Idris A (2010) Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Current Neuropharmacology, 8(3), 243-253.
Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van't Hof RJ & Ralston SH (2009) Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 10(2), 139-147.
Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D & Ralston SH (2009) Pharmacologic inhibitors of I B kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Molecular Cancer Therapeutics, 8(8), 2339-2347.
Idris AI, Sophocleous A, Landao-Bassonga E, Merkouris M, Milligan GI, Baker D, van't Hof RJ & Ralston SH (2009) Cannabinoid receptor type 1 protects against age-related bone loss by regulating osteoblast and adipocyte differentiation of bone marrow stromal cells. Bone, 44, S222-S222.
Coste E, Rose L, Greig IR, Idris AI, Ralston SH & van 't Hof RJ (2009) A small molecule inhibitor of RANKL- and TNF-induced signalling prevents ovariectomy-induced bone loss and inflammation in collagen induced arthritis. Bone, 44, S244-S245.
Sophocleous⁎ A, Landao-Bassonga E, van't Hof R, Ralston SH & Idris AI (2009) The type 2 cannabinoid receptor (CB2) protects against age-related osteoporosis by affecting bone formation and CB2 agonists exhibit anabolic activity in vivo. Bone, 44, S219-S219.
Pitsillides A, Salmon P, Tivesten A, Moverare-Skrtic S, Ohlsson C, Oste L, Dixon G, Grieg I, Idris A, Van T'Hof R , Le V et al (2009) Profile analysis of metaphyseal trabecular bone in rodent ovariectomy models reveals a bimodal dose-dependent response to administered bone active agents. Bone, 44, S155-S156.
Pathan E, Coste E, Rose L, Idris AI, Daroszewska A, Greig IR, Gray M, Ralston SH & van't Hof RJ (2009) NOVEL SMALL MOLECULE INHIBITORS OF TNF- AND RANKL-SIGNALING PREVENT COLLAGEN INDUCED ARTHRITIS. RHEUMATOLOGY, 48, I40-I40.
Aitken SJ, Landao-Bassonga E, Ralston SH & Idris AI (2009) β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Archives of Biochemistry and Biophysics, 482(1-2), 96-103.
Idris AI, Ralston SH & van't Hof RJ (2009) The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. European Journal of Pharmacology, 602(2-3), 215-222.
Idris AI, Greig IR, Bassonga-Landao E, Ralston SH & van 't Hof RJ (2009) Identification of Novel Biphenyl Carboxylic Acid Derivatives as Novel Antiresorptive Agents that Do Not Impair Parathyroid Hormone-Induced Bone Formation. Endocrinology, 150(1), 5-13.
Idris AI (2008) Role of cannabinoid receptors in bone disorders: Alternatives for treatment. Drug News and Perspectives, 21(10), 533-540.
Idris AI, Sophocleous A, Landao-Bassonga E, van't Hof RJ & Ralston SH (2008) Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor. Endocrinology, 149(11), 5619-5626.
Idris A, Mrak E, Greig I, Guidobono F, Ralston SH & van ’t Hof R (2008) ABD56 causes osteoclast apoptosis by inhibiting the NFκB and ERK pathways. Biochemical and Biophysical Research Communications, 371(1), 94-98.
Aitken S, Landao-Bassonga E, Ralston SH & Idris AI (2008) Beta-2 adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Bone, 42, S34-S35.
Idris AI, Rojas J, Greig IR, van’t Hof RJ & Ralston SH (2008) Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro. Calcified Tissue International, 82(3), 191-201.
Idris AI, Simic P, Krishnan M, Vikicevic S & Ralston SH (2008) Small molecule inhibitors of IKK-dependent signalling inhibit osteoclast formation in vitro and ovariectomy-induced bone loss in vivo. CALCIFIED TISSUE INTERNATIONAL, 82, S32-S32.
Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D & Ralston SH (2008) The IKK inhibitors celastrol and parthenolide inhibit breast cancer cell proliferation and migration in vitro and osteolytic bone metastasis in vivo. CALCIFIED TISSUE INTERNATIONAL, 82, S49-S49.
Coste E, Rose L, Idris AI, Greig I, Gray M, Ralston SH & van't Hof RJ (2008) The novel biphenyl ketone ABD345 inhibits Nf-kappa-B activation, inflammation and joint destruction in collagen induced arthritis. CALCIFIED TISSUE INTERNATIONAL, 82, S136-S136.
Sophocleous A, Landao-Bassonga E, van't Hof R, Ralston SH & Idris AI (2008) Cannabinoid receptor antagonists inhibit osteoclast formation in vitro and ovariectomy-induced bone loss in vivo through the CB1 and CB2 receptors. CALCIFIED TISSUE INTERNATIONAL, 82, S31-S31.
Sophocleous A, Landao-Bassonga E, van't Hof R, Idris AI & Ralston SH (2008) Cannabinoid receptor 2 selective agonists stimulate osteoclast formation in vitro but act as anabolic agents in vivo by stimulating bone formation. CALCIFIED TISSUE INTERNATIONAL, 82, S118-S118.
Idris AI, Sophocleous A, Landao-Bassonga E, van't Hof R & Ralston SH (2008) Bidirectional regulation of peak bone mass and age-related bone loss by the type I cannabinoid receptor. CALCIFIED TISSUE INTERNATIONAL, 82, S57-S57.
Hughes A, Rogers MJ, Idris AI & Crockett JC (2007) A Comparison between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function In Vitro and Ovariectomy-Induced Bone Loss In Vivo. Calcified Tissue International, 81(5), 403-413.
Idris AI, Rojas JA, Greig IR, van't Hof RJ & Ralston SH (2007) Nitrogen-containing bisphosphonates inhibit bone mineralization in vitro via a mechanism independent of inhibition of protein prenylation. CALCIFIED TISSUE INTERNATIONAL, 80, S79-S79.
Idris AI, Greig IR, Ralston SH & van't Hof RJ (2007) Biphenylcarboxylates inhibit bone resorption in vitro and ovariectomy induced bone loss in vivo without impairing PTH induced bone formation. CALCIFIED TISSUE INTERNATIONAL, 80, S28-S28.
Sophocleous A, Lanclao-Bassonga E, van't Hof RJ, Idris AI & Ralston SH (2007) Cannabinoid receptor agonists are potential bone anabolic agents which stimulate bone formation in vitro and increase bone mass in vivo. CALCIFIED TISSUE INTERNATIONAL, 80, S32-S32.
Idris AI, Greig IR, Gray M, Ralston SH & van't Hof RJ (2007) Small molecule inhibitors of TRAF-dependent signaling as anti resorptive and anti-rheumatic drugs. CALCIFIED TISSUE INTERNATIONAL, 80, S33-S33.
Greig IR, Idris AI, Ralston SH & van't Hof RJ (2006) Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption. Journal of Medicinal Chemistry, 49(25), 7487-7492.
Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA & Ralston SH (2005) Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nature Medicine, 11(7), 774-779.
Van 't Hof RJ, Idris AI, Ridge SA, Dunford J, Greig IR & Ralston SH (2004) Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors.. J Bone Miner Res, 19(10), 1651-1660.
Idris AI, Del Soldato P, Ralston SH & van't Hof RJ (2004) The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production. Bone, 35(3), 636-643.
Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Ross RA & Ralston SH (2004) CANNABINOID RECEPTOR ANTAGONISTS INHIBIT OSTEOCLASTIC BONE RESORPTION IN VITRO AND PREVENT OVARIECTOMY INDUCED BONE LOSS IN VIVO. CALCIFIED TISSUE INTERNATIONAL, 74, S34-S34.
Idris AI, Greig IR, Ralston SH & Van't Hof RJ (2004) ABD56 A POTENT INHIBITOR OF BONE RESORPTION, INDUCES OSTEOCLAST APOPTOSIS VIA NFKB AND ERK INHIBITION IN VITRO. CALCIFIED TISSUE INTERNATIONAL, 74, S35-S35.
Peramuhendige P, Marino S, Mollat P & Idris AI () TRAF2, but not TRAF6, regulates breast cancer induced osteoclastogenesis and osteolysis.. Bone Abstracts.
Marino S, Logan JG, Sophocleous A, Mollat P, Mognetti B, Ventura L, Sims AH, Rucci N, Ralston SH & Idris AI () Regulation of bone metastasis by the IKK[beta]/FoxO3a axis. Bone Abstracts.
van 't Hof RJ, Idris AI, Ridge SA, Dunford J, Greig IR & Ralston SH () Identification of Biphenylcarboxylic Acid Derivatives as a Novel Class of Bone Resorption Inhibitors. Journal of Bone and Mineral Research, 19(10), 1651-1660.

Chapters

Idris AI (2020) Role of NFκB in Bone Remodeling in Health and Cancer, Encyclopedia of Bone Biology (pp. 294-304). Elsevier
Sophocleous A & Idris AI (2019) Ovariectomy/Orchiectomy in Rodents, Methods in Molecular Biology (pp. 261-267). Springer New York
Marino S & Idris AI (2019) Analysis of Signaling Pathways by Western Blotting and Immunoprecipitation, Methods in Molecular Biology (pp. 131-143). Springer New York
Idris A (2012) Aymen I. Idris Ovariectomy and Orchidectomy in Rodents., Bone Research Protocols. Totowa, NJ: Humana Press
Idris A (2010) Analysis of Signalling Pathways in Bone Cells. T, Bone Research Protocols. 2nd ed. Humana Press

Conference proceedings papers

Marino⁎ S, Logan JG, Mollat P, Mognetti B, Ralston SH & Idris AI (2012) Genetic inactivation and pharmacological inhibition of IKKβ activity in cancer cells inhibit breast cancer-induced osteoclastogenesis, promotes osteoblast differentiation and prevents osteolysis. Bone, Vol. 50 (pp S51-S51)
Sophocleous⁎ A, Ralston SH & Idris AI (2012) Combined deficiency of the CB1 and CB2 receptors enhances peak bone mass by inhibiting osteoclast differentiation but increases age-related bone loss by promoting adipocyte differentiation and reducing osteoblast differentiation. Bone, Vol. 50 (pp S32-S32)
Peramuhendige⁎ P, Marino S, Unciti-Broceta A, Ralston SH & Idris AI (2012) A novel small molecule inhibitor of TRAF-dependent signalling inhibits breast cancer-induced osteoclastogenesis and prevents osteolysis. Bone, Vol. 50 (pp S61-S62)
Logan JG, Sophocleous A, Landao-Bassonga E, Brunton VG & Idris AI (2011) The novel and selective insulin-like growth factor-1 receptor kinase inhibitor pqip suppresses bone cell function and osteoclast- breast cancer cell cross-talk. Bone, Vol. 48 (pp S257-S257)
Sophocleous A, Ralston SH & Idris AI (2011) Genetic disruption of both the CB1 and the CB2 receptor in mice enhances trabecular bone mass but reduces cortical bone mass. Bone, Vol. 48 (pp S127-S127)
Sophocleous A, Logan JG, Mackintosh A, Landao-Bassonga E, Ralston SH & Idris AI (2011) The CB2 receptor regulates osteoclast formation, breast cancer cell migration and osteoclast/tumour cell interaction via the PI3 Kinase/AKT pathway. Bone, Vol. 48 (pp S73-S74)
Idris* AI, Frantzias J, Mollat P, Sparatore A, Del Soldato P & Ralston SH (2011) Identification of hydrogen sulfide releasing compounds as novel antiresorptive and antitumour agents. Bone, Vol. 48(1) (pp S44-S44)
Logan* JG, Landao-Bassonga E, Brunton VG & Idris AI (2011) The novel and selective insulin-like growth factor-1 receptor kinase inhibitor PQIP suppresses bone cell function and osteoclast-breast cancer cell cross-talk in vitro. Bone, Vol. 48(1) (pp S43-S43)
Sophocleous* A, Mackintosh A, Landao-Bassonga E, Ralston SH & Idris AI (2011) Peripheral cannabinoid type 2 receptor regulates osteoclast formation, MDA-MB-231 breast cancer cell migration and bone marrow/tumour cell interaction via PI3 kinase/AKT and P38 pathways. Bone, Vol. 48(1) (pp S44-S44)
Salmon P, Pitsillides A, Tivesten A, Moverare-Skrtic S, Ohlsson C, Oste L, Dixon G, Idris A & T'Hof RV (2008) A novel profile analysis of metaphyseal trabecular bone reveals a biphasic dose-dependent response to administered bone active agents. Bone, Vol. 43 (pp S19-S19)
Pitsillides A, Salmon PL, Tivesten A, Moverare-Skrtic S, Ohlsson C, Oste L, Dixon G, Idris A & Van T'Hof R (2008) Profile Analysis of Rodent Metaphyseal Trabecular Bone Reveals a Biphasic Dose-Dependent Response To Administered Bone Active Agents. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S220-S220)
Sophocleous A, Landao E, vant Hof R, Idris AI & Ralston SH (2008) Cannabinoid receptor 2 selective agonists stimulate osteoclast formation in vitro but act as anabolic agents in vivo by stimulating bone formation. Bone, Vol. 42 (pp S31-S31)
Idris A, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D & Ralston S (2008) P52. The IKK inhibitors celastrol and parthenolide inhibit breast cancer cell proliferation and migration in vitro and osteolytic bone metastasis in vivo. Cancer Treatment Reviews, Vol. 34 (pp 75-75)
Hughes A, Crockett JC, Idris AI, van't Hof RJ & Rogers MJ (2005) Rosuvastatin inhibits bone resorption in vitro by inhibiting protein prenylation, and prevents ovariectomy-induced bone loss in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S260-S260)
Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA & Ralston SH (2005) Cannabinoid receptor 1 knockout mice have increased bone mass and are protected from ovariectomy-induced bone loss. BONE, Vol. 36 (pp S132-S132)
Idris AI, Greig IR, Ralston SH & van't Hof RJ (2005) ABD56 is a potent inhibitor of RANKL- and TNF-stimulated NF kappa B and ERK activation in vitro. RHEUMATOLOGY, Vol. 44 (pp I36-I36)
Idris AI, Van't Hof' RJ, Greig IR, Ridge SA, Baker D, Ross RA & Ralston SH (2004) Regulation of osteoclastic bone resorption and bone mass by the cannabinoid receptor 1 pathway.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S284-S284)
Idris A, Greig L, Ridge S, Ralston S & van't Hof R (2004) Identification of biphenyl-carboxylic acid derivatives as a novel class of bone resorption inhibitors. BONE, Vol. 34 (pp S22-S23)
Idris AI, van't Hof RJ, Greig IR, Ridge SA, Ross RA & Ralston SH (2004) Cannabinoid receptor antagonists inhibit osteoclastic bone resorption in vitro and prevent ovariectomy induced bone loss in vivo. BONE, Vol. 34 (pp S22-S22)

Patents

Idris A (2009) Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions. PCT/GB2004/001958 Appl. 11 Aug 2009.
Idris A (2006) Aryl Alkyl Sulfonamides as therapeutic agents for the treatment of bone conditions. PCT/GB2005/002043 Appl. 26 Jan 2006.
Idris A (2004) Cannabinoid receptor inverse agonists as therapeutic agents for the treatment of bone disorders. PCT/GB2004/000858 Appl. 16 Sep 2004.

Other

Idris AI (2018) Recent Trends and Advances in Cancer-Induced Bone Disease. Calcified Tissue International, 102(2), 129-130.

Teaching interests

Supervise undergraduates, MSc and PhD students in my laboratory
Teach a module on hypothesis testing and experimental design in medical research
Teach and run tutorials on research skills to PhD students
Act as lead tutor to postgraduate students
Act as personal academic tutor to medical, MSc and PhD students

Professional activities

Founder of the cloud-based software PubFund.
Editor, Springer Bone Research Protocols, 3rd edition (2019)
Editor-in-Chief and Founder, HubLE - The IFMRS Learning Environment (2019)
Associated editor at BoneKEy Reports (2013 - 2017)
Member of editorial board of Calcified Tissue International
Editor, Cancer and Bone, Calcified Tissue International (February, 2018)
Member of British Pharmacological Society (BPS), European Calcified Tissue Society (ECTS), International Bone and Mineral Society (IBMS) and American Society for Bone and Mineral Research (ASBMR).
Ad hoc reviewer for a number of national and international science journals and research charities.
Board member of the Calcified Tissue International Society (ECTS, 2010 – 2013).
Founder of the ECTS Postdoc Gathering and co-founder of ECTS New Investigator Seminar.
Co-founder and chair of the ECTS New Investigator Committee (2010 – 2013).

Startup Companies

PF SYSTEM Ltd - Founder of PF System Ltd. (Registration No: 11983932), a company established to develop the cloud-based software, PubFund in collaboration with a team of independent software engineers.
ArthElix Ltd - Founder and shareholder of ArthElix Ltd. (Registration No: 10597512), a company established in 2017 to develop and test novel TRAF/NFkB inhibitors as a novel class of anti-rheumatic and anti-metastatic drugs.
OSTEORX LIMITED - Co-founder and shareholder of OSTEORX LIMITED (Registration No: SC288265), a company established in 2005 to develop biphenyl-carboxylic acid compounds and their non-hydrolysable derivatives as a novel class of anti-rheumatic drugs. OSTEORX LIMITED and Modern Biosciences plc. have recently entered into an R&D alliance and global option and licence agreement with Janssen Biotech, Inc.

Awards

Young investigator award (ECTS, 2007)
AMGEN/ECTS Bone Biology Fellowship
Young investigator award (ECTS, 2006)
IBMS Young investigator award (ECTS, 2005)
Young investigator award (ECTS, 2004)
Frontiers of Skeletal Biology Young investigator award (2002)